Sirolimus in Conjunction With Eylea vs Eylea Alone for Exudative AMD
Status:
Completed
Trial end date:
2017-04-04
Target enrollment:
Participant gender:
Summary
To determine safety and efficacy of intravitreal injections of Sirolimus with adjunct EYLEA
in subjects with exudative age related macular degeneration (AMD) with persistent
intraretinal or subretinal edema due to neovascular AMD despite previous intravitreal
anti-vascular endothelial growth factor (antiVEGF) treatment.